Back to Journals » Drug Design, Development and Therapy » Volume 15

Efficacy and Safety of Retinol Palmitate Ophthalmic Solution in the Treatment of Dry Eye: A Japanese Phase II Clinical Trial [Corrigendum]

Authors Toshida H, Funaki T, Ono K, Tabuchi N, Watanabe S, Seki T, Otake H, Kato T, Ebihara N, Murakami A

Received 11 January 2021

Accepted for publication 11 January 2021

Published 24 February 2021 Volume 2021:15 Pages 813—816

DOI https://doi.org/10.2147/DDDT.S301482


Toshida H, Funaki T, Ono K, et al. Drug Des Devel Ther.  2017;11:1871– 1879

The authors have advised there are some mistakes in the mean changes and standard errors of the paper:
1. The standard errors of groups Placebo and VApal were all the same value for staining and symptom scores in Figure 1 (on page 1875) and Figure 3 (on page 1876), and Table 3 (on page 1877).
2. There were slight discrepancies in the Mean changes of Placebo group at 1, 2 and 4 weeks in Figure 3D.
3. There was a slight discrepancy in the Mean change of foreign body sensation in Placebo group at 1 week in Table 3.

The authors have advised the errors were due to:
1. The standard error listed in a different table on the statistical analysis software was adopted.
2. There were typing errors when transferring numerical values from statistical analysis software to graph creation software.
3. There was a mistake when rounding numerical value.

Since the statistical analysis had been performed using the original mean values (correct values), all results do not change.

The authors apologize for these errors and advise they do not affect the results of the paper.

Read the original article


Toshida H, Funaki T, Ono K, et al. Drug Des Devel Ther. 2017;11:1871–1879

The authors have advised there are some mistakes in the mean changes and standard errors of the paper:

1. The standard errors of groups Placebo and VApal were all the same value for staining and symptom scores in Figure 1 (on page 1875) and Figure 3 (on page 1876), and Table 3 (on page 1877).

Figure 1 Mean change in staining score.

Abbreviations: RB, rose bengal; VApal, retinol palmitate.

Notes: Mean change in fluorescein staining score (A) and RB staining score (B) from baseline to 1, 2, and 4 weeks. *P<0.05. **P<0.01 versus placebo (unpaired t-test).

Figure 3 Mean change in symptom score.

Abbreviation: VApal, retinol palmitate.

Notes: Mean change in symptom scores for dryness (A), blurred vision (B), heaviness (C), itching (D), and eye discharge (E) and total score for subjective symptoms (F) from baseline to 1, 2, and 4 weeks. *P<0.05. **P<0.01 versus placebo (unpaired t-test).

Table 3 Mean Change in Symptom Score

2. There were slight discrepancies in the Mean changes of Placebo group at 1, 2 and 4 weeks in Figure 3D.

3. There was a slight discrepancy in the Mean change of foreign body sensation in Placebo group at 1 week in Table 3.

The authors have advised the errors were due to:

1. The standard error listed in a different table on the statistical analysis software was adopted.

2. There were typing errors when transferring numerical values from statistical analysis software to graph creation software.

3. There was a mistake when rounding numerical value.

Since the statistical analysis had been performed using the original mean values (correct values), all results do not change. 

The authors apologize for these errors and advise they do not affect the results of the paper.

The updated Figures and Table are shown below.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]